Literature DB >> 9333177

Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly.

U Sankilampi1, P O Honkanen, A Bloigu, M Leinonen.   

Abstract

Persistence of antibodies to 23-valent pneumococcal vaccine was assessed among 62 subjects aged 65-88 years. IgG antibodies were measured by standardized EIA to serotypes 4, 6B, 9V, 14, 19F, and 23F before and 1 month, 1 year, and 3 years after vaccination. After satisfactory antibody responses (fold increases from 2.6 to 5.3), 3-year geometric mean concentrations (GMCs) had waned to close (for types 4, 9V, and 23F) or similar (for types 6B and 19F) to their prevaccination values. Type 14 was exceptional: 1-month GMC was 7.7-fold and 3-year GMC was 3.0-fold in comparison to the prevaccination GMC. Antibody concentrations decreased at an equal rate irrespective of serotype and age or sex of the vaccinee. The major factor predicting the persistence of antibodies above the prevaccination level was the magnitude of the original antibody response. Present results suggest that pneumococcal revaccination of the elderly may be needed as early as 3-4 years after the initial vaccination.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9333177     DOI: 10.1086/516521

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Comparative immune responses of patients with chronic pulmonary diseases during the 2-year period after pneumococcal vaccination.

Authors:  Meng Chen; Yuki Hisatomi; Akitsugu Furumoto; Kenji Kawakami; Hironori Masaki; Tsuyoshi Nagatake; Yoshiko Sueyasu; Tomoaki Iwanaga; Hisamichi Aizawa; Kazunori Oishi
Journal:  Clin Vaccine Immunol       Date:  2006-12-13

2.  The immune response to pneumococcal polysaccharides 14 and 23F among elderly individuals consists predominantly of switched memory B cells.

Authors:  David J Leggat; Rebecca S Thompson; Noor M Khaskhely; Anita S Iyer; M A Julie Westerink
Journal:  J Infect Dis       Date:  2013-04-01       Impact factor: 5.226

3.  Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination.

Authors:  M A Julie Westerink; Harry W Schroeder; Moon H Nahm
Journal:  Aging Dis       Date:  2011-07-20       Impact factor: 6.745

4.  V(H)3 antibody response to immunization with pneumococcal polysaccharide vaccine in middle-aged and elderly persons.

Authors:  Jose A Serpa; Josemon Valayam; Daniel M Musher; Roger D Rossen; Liise-anne Pirofski; Maria C Rodriguez-Barradas
Journal:  Clin Vaccine Immunol       Date:  2011-01-12

5.  Beliefs, attitudes, and activities of healthcare personnel about influenza and pneumococcal vaccines.

Authors:  Fatma Çiftci; Elif Şen; Nalan Demir; Orçun Çiftci; Serhat Erol; Oya Kayacan
Journal:  Hum Vaccin Immunother       Date:  2017-11-29       Impact factor: 3.452

Review 6.  Pneumococcal vaccination for older adults: the first 20 years.

Authors:  D S Fedson
Journal:  Drugs Aging       Date:  1999       Impact factor: 3.923

7.  Measurement and interpretation of pneumococcal IgG levels for clinical management.

Authors:  P Balmer; J North; D Baxter; E Stanford; A Melegaro; E B Kaczmarski; E Miller; R Borrow
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

8.  Pneumococcal vaccines: understanding centers for disease control and prevention recommendations.

Authors:  Mehdi Mirsaeidi; Dean E Schraufnagel
Journal:  Ann Am Thorac Soc       Date:  2014-07

Review 9.  Pneumococcal vaccination and revaccination of older adults.

Authors:  Andrew S Artz; William B Ershler; Dan L Longo
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

Review 10.  A systems biology approach to the effect of aging, immunosenescence and vaccine response.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Richard B Kennedy; Nathaniel D Lambert; James L Kirkland
Journal:  Curr Opin Immunol       Date:  2014-05-13       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.